← Back to Search

Vitamin D Production Stimulator

Phototherapy for Multiple Sclerosis

Phase 1
Waitlist Available
Led By Robert W Motl, PhD
Research Sponsored by University of Illinois at Urbana-Champaign
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female with multiple sclerosis
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0, 4, and 8 weeks
Awards & highlights

Study Summary

The current study examines the effect of phototherapy equipped with Narrow Band UVB lamps on vitamin D production in persons with MS.

Eligible Conditions
  • Multiple Sclerosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 4, and 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 4, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Serum Vitamin D at 4 and 8 weeks
Secondary outcome measures
Change from Baseline in Cognitive Function at 4 and 8 weeks
Change from Baseline in Mood State at 4 and 8 weeks
Change from Baseline in Walking Speed at 4 and 8 weeks

Side effects data

From 2016 Phase 2 trial • 91 Patients • NCT01887327
17%
Cardiac murmur
17%
Erythema
13%
Umbilical hernia
10%
Rash
10%
Seborrhoeic dermatitis
7%
Haemolytic anaemia
7%
Haemoglobin decreased
7%
Hyperbilirubinaemia
7%
Dry skin
7%
Medical observation
7%
Thrombocytopenia
7%
Reticulocyte count increased
7%
Dermatitis diaper
7%
Rash maculo-papular
7%
Gamma-glutamyl transferase increased
7%
Seborrhoea
3%
Aspartate Aminotransferase Increased
3%
Tachypnoea
3%
Ankyloglossia Congenital
3%
Vomiting
3%
Conjucunctival Hemorrhage
3%
Lethargy
3%
Melanosis
3%
Patent Ductus Arteriosus
3%
Haematocrit Abnormal
3%
Ventricular Hypertrophy
3%
Eye Discharge
3%
Anaemia
3%
Haematocrit decreased
3%
Infantile Vomiting
3%
Erythema toxicum neonatorum
3%
Skin Sensitisation
3%
Bilirubin Conjugated Increased
3%
Skin Hyperpigmentation
3%
Rash Erythematous
3%
Cough
3%
Leukocytosis
3%
Supraventricular Tachycardia
3%
Atrial Septal Defect
3%
Constipation
3%
Infantile Colic
3%
Candida Nappy Rash
3%
Skin Candida
3%
Sunburn
3%
Respiratory Syncytial Virus Test Positive
3%
Tremor
3%
Umbilical Granuloma
3%
Acne infantile
3%
Viral Infection
3%
Hyperkalaemia
3%
Hypocalcaemia
3%
Nasal Congestion
3%
Milia
3%
Supraventricular tachycardia
100%
80%
60%
40%
20%
0%
Study treatment Arm
3.0 mg/kg Stannsoporfin
4.5mg/kg Stannsoporfin
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PhototherapyExperimental Treatment1 Intervention
This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
Group II: Shame phototherapyPlacebo Group1 Intervention
This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phototherapy
2021
Completed Phase 4
~750

Find a Location

Who is running the clinical trial?

University of Illinois at Urbana-ChampaignLead Sponsor
189 Previous Clinical Trials
37,365 Total Patients Enrolled
15 Trials studying Multiple Sclerosis
665 Patients Enrolled for Multiple Sclerosis
Robert W Motl, PhDPrincipal InvestigatorUniversity of Illinois at Urbana-Champaign
7 Previous Clinical Trials
851 Total Patients Enrolled
7 Trials studying Multiple Sclerosis
851 Patients Enrolled for Multiple Sclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phototherapy in Persons With Multiple Sclerosis
2015. "Phototherapy in Persons With Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02365259.
All > Primary Progressive Multiple Sclerosis
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top